Home › Companies › XENE

Xenon Pharmaceuticals

XENE Rare disease Lead: Phase 3 2 Biotech Distilled articles ↓

Neurology Small Molecule

Most recent annual filing: 2026-02-26

Catalyst timeline

3 trackedQuarter catalyst calendar →

XEN1701/XEN1120 Ph1 readout2026XEN1701/XEN1120 Ph1 readout, 2026, notable
Azetukalner NDA filing3Q 2026Azetukalner NDA filing, 3Q 2026, notable
Azetukalner MDD Ph3 topline1H 2027Azetukalner MDD Ph3 topline, 1H 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

azetukalner

XEN1101

Small Molecule Target: Kv7 potassium channel, Kv7

Focal Onset Seizures Phase 3 oral NCT03796962
Major Depressive Disorder Phase 3 oral NCT05376150
Bipolar Depression Phase 3 oral NCT07172516

XEN1701

Small Molecule Target: Nav1.7

Acute Pain Phase 1

XEN1120

Small Molecule Target: Kv7 potassium channel, Kv7

Acute Pain Phase 1

NBI-921355

Small Molecule Target: Nav1.2, Nav1.6

Epilepsy Phase 1 Neurocrine Biosciences

Nav1.1 program

Small Molecule Target: Nav1.1

Dravet Syndrome Preclinical

XEN1720

Small Molecule Target: Nav1.7

Undisclosed indication Phase 1

Biotech Distilled coverage (2)

2026-08-07 UPDATE: Xenon Pharmaceuticals (XENE) - The Filing Window Opens 🔒 Paid
2026-05-02 Xenon Pharmaceuticals (XENE) - Scientific Deep Dive for Azetukalner and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.